摘要
目的了解医院2008-2012年核苷类抗肝炎药物的应用情况,分析核苷类抗肝炎药物使用的特点和趋势,为临床合理用药和科学管理提供参考。方法收集医院2008-2012年4种核苷类抗肝炎药物的使用资料,对用药金额、用药种类、用药频度(DDDs)等进行分析。结果 2008-2012年4种核苷类抗肝炎药物的销售金额构成比呈逐年增长趋势;4种核苷类抗肝炎药物中,阿德福韦酯的销售金额及其构成比和DDDs均稳居榜首,销售金额逐年增长,从552.08万增长至1023.49万,但销售金额构成比却呈现逐年降低的趋势,从52.84%降至38.78%;5年内恩替卡韦的销售金额和DDDs的增幅最大,分别增加了4.1倍和4.9倍。结论核苷类抗肝炎药物的使用正逐步规范化,该类药物仍是目前治疗病毒性肝炎的主要药物。
OBJECTIVE To investigate the utilization condition of anti‐hepatitis nucleoside drugs in a hospital from the year 2008 to 2012 ,analyze the usage characteristics and tendency so as to provide references for the rational use and scientific management of anti‐hepatitis nucleoside drugs .METHODS The consumption data about the anti‐hepatitis nucleoside drugs in the hospital during 2008 -2012 were collected for analysis of consumption sum , categories and DDDs ,etc .RESULTS From the year 2008 to 2012 ,the constituent ratio of sales amount of anti‐hepatitis nucleoside drugs increased year by year . In the 4 anti‐hepatitis nucleoside drugs , sales amount , constituent ratio for sales amount and DDDs of Adefovir Dipivoxil ranked the top ,its sales amount increased year by year from 5 ,520 ,800 yuan to 10 ,234 ,900 yuan ,but the constituent ratio for its sales amount decreased year by year ,falling from 52 .84% to 38 .78% .Entecavir had the highest increase of sales amount and DDDs in the five years ,increased by 4 .1 fold and 4 .9 fold .CONCLUSION The utilization of anti‐hepatitis nucleoside drugs is under standardization ,and these drugs are still the main drugs for treatment of viral hepatitis .
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2015年第11期2476-2477,2523,共3页
Chinese Journal of Nosocomiology
基金
南京市医学科技发展基金资助项目(YKK13156)
